Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)

CONCLUSIONS: A single dose of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume growth, but natalizumab appeared to be associated with important functional outcome improvements sustained over 90 days. Further natalizumab studies for AIS are warranted. Support: Biogen.Disclosure: Dr. Elkins holds stock and/or stock options in Biogen, which sponsored research in which Dr. Elkins was involved as a researcher. Dr. Elkind has received personal compensation in and editorial capacity for serving as an Associate Editor of the journal Neurology. Dr. Veltkamp has received research support from Bayer, BMS, Boehringer Ingelheim, and Daiichi Sankyo. Dr. Montaner has received personal compensation for activities with Biogen. Dr. Montaner has received personal compensation in an editorial capacity for Translational Proteomics. Dr. Johnston received research support from AstraZeneca. Dr. Singhal has received personal compensation for activities with Medicolegal as an expert witness and ACTION Trial Stroke Advisory Board and Biogen as a consultant. Dr. Singhal holds stock and/or stock options in Biogen Idec. Dr. Singhal has received re Dr. Becker has received research support from NIH and AHA. Dr. Lansberg has received personal compensation for activities with Biogen as a scientific advisory board participant. Dr. Ih Chang holds stock options in Biogen, which sponsored research in which Dr. Chang was involved as an investigator. Dr. Tang holds stoc...

Source: Neurology - April 3, 2016 Category: Neurology Authors: Elkins, J., Elkind, M., Veltkamp, R., Montaner, J., Johnston, S., Singhal, A., Becker, K., Lansberg, M., Chang, I., Tang, W., Gheuens, S., Mehta, L. Tags: Stroke Clinical Trials Source Type: research